Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial

Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial

Bibliographic Details
Main Authors:	Li, Feng-fei, Jiang, Lan-lan, Yan, Reng-na, Zhu, Hong-hong, Zhou, Pei-hua, Zhang, Dan-feng, Su, Xiao-fei, Wu, Jin-dan, Ye, Lei, Ma, Jian-hua
Format:	Online
Language:	English
Published:	Wolters Kluwer Health 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089116/

Similar Items

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
by: Neumiller, Joshua J.
Published: (2014)

Influence of Acarbose on Plasma Glucose Fluctuations in Insulin-Treated Patients with Type 2 Diabetes: A Pilot Study
by: Li, Feng-fei, et al.
Published: (2015)

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
by: Li, Feng-fei, et al.
Published: (2016)

Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
by: Liu, Hao, et al.
Published: (2016)

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
by: Iqbal, Nayyar, et al.
Published: (2014)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
by: Karyekar, Chetan S, et al.
Published: (2013)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
by: Li, Chun-Jun, et al.
Published: (2014)

Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections
by: Li, Feng-fei, et al.
Published: (2016)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
by: Pia S. Pollack, et al.
Published: (2017-09-01)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
by: Vaidya, Varun, et al.
Published: (2016)

Lixisenatide as add-on therapy to basal insulin
by: Brown, Dominique Xavier, et al.
Published: (2013)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
by: Borgohain, Rupam, et al.
Published: (2014)

Relationship between Serum Lipoprotein Ratios and Insulin Resistance in Polycystic Ovary Syndrome
by: Xiang, Shou-Kui, et al.
Published: (2012)

Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study
by: Sagduyu, Kemal, et al.
Published: (2005)

Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder
by: Berlant, Jeffrey L
Published: (2004)

An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients
by: Carta, Mauro Giovanni, et al.
Published: (2006)

Effects of Add-on Ramelteon on Cognitive Impairment in Patients with Schizophrenia: An Open-label Pilot Trial
by: Shirayama, Yukihiko, et al.
Published: (2014)

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
by: Kim, Jong-Min, et al.
Published: (2015)

Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment
by: Wang, Lin, et al.
Published: (2016)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
by: Cobble, Michael E, et al.
Published: (2012)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
by: Elgart, Jorge F, et al.
Published: (2013)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
by: Minze, Molly G., et al.
Published: (2013)

Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin
by: Doggrell, Sheila A
Published: (2014)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
by: Ott, Christian, et al.
Published: (2014)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
by: Panagoulias, George S, et al.
Published: (2014)

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
by: Perl, Shira, et al.
Published: (2016)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
by: Jain, Rajeev
Published: (2015)

Saxagliptin Restores Vascular Mitochondrial Exercise Response in the Goto-Kakizaki Rat
by: Keller, Amy C., et al.
Published: (2015)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
by: Konya, Hiroyuki, et al.
Published: (2014)

Fluctuating hydrodynamics, current fluctuations and hyperuniformity in boundary-driven open quantum chains
by: Carollo, Federico, et al.
Published: (2017)

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
by: Li, Chun-jun, et al.
Published: (2012)

Common Marker Genes Identified from Various Sample Types for Systemic Lupus Erythematosus
by: Bing, Peng-Fei, et al.
Published: (2016)

Chronic unpredicted mild stress-induced depression alter saxagliptin pharmacokinetics and CYP450 activity in GK rats
by: Xia, Zhengchao, et al.
Published: (2016)

Oxamate Improves Glycemic Control and Insulin Sensitivity via Inhibition of Tissue Lactate Production in db/db Mice
by: Ye, Weiran, et al.
Published: (2016)

Adds
by: Co-Editors – Co-Editoras
Published: (2012-02-01)

Glycemic variability in normal glucose tolerance women with the previous gestational diabetes mellitus
by: Wang, Yong-mei, et al.
Published: (2015)

Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
by: Birnbaum, Yochai, et al.
Published: (2016)

Impact of Alcohol on Glycemic Control and Insulin Action
by: Steiner, Jennifer L., et al.
Published: (2015)

Achieving glycemic control with intensive insulin therapy in the ICU
by: Vakalos, A, et al.
Published: (2008)

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
by: Perkins, Bruce A., et al.
Published: (2015)